These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 14667953

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [Abstract] [Full Text] [Related]

  • 5. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM, Saini R, Tutrone WD.
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Bottino CJ, Lindholm J, Buchholz R.
    J Drugs Dermatol; 2005 Dec; 4(5):544-55. PubMed ID: 16167412
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [Abstract] [Full Text] [Related]

  • 9. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ, Bello-Quintero CE.
    J Manag Care Pharm; 2004 Aug; 10(4):318-25. PubMed ID: 15298530
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [Abstract] [Full Text] [Related]

  • 12. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD.
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Oct; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 15. Understanding the new clinical landscape for psoriasis: a comparative review of biologics.
    Sauder DN, Mamelak AJ.
    J Cutan Med Surg; 2004 Oct; 8(4):205-12. PubMed ID: 16091996
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment.
    Anstey AV, Kragballe K.
    Int J Dermatol; 2006 Aug; 45(8):970-5. PubMed ID: 16911387
    [Abstract] [Full Text] [Related]

  • 18. Biologicals in the treatment of psoriasis.
    Boker A, Kimball AB, Rolz-Cruz G.
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [Abstract] [Full Text] [Related]

  • 19. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A, Talamonti M, Botti E, Spallone G, Papoutsaki M, Chimenti S.
    Dermatology; 2009 Jun; 219(1):48-53. PubMed ID: 19372639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.